Co-Dev Deals Are Up 1200% in 2026 — Here's the Data

Twelve co-development deals closed between March and September 2026, up from exactly zero in the prior six-month period — a 1200% surge that marks the most dramatic structural shift in biopharma partnering this year. This isn't a rounding error or a seasonal blip. When AbbVie, Amgen, AstraZeneca, Janssen, and Novartis all pivot toward co-development structures within the same window, it signals a market-wide repricing of how pipeline risk gets shared between partners.

The Data — Co-Dev Deal Activity, Period over Period

The baseline of zero matters. Co-development deals — where both parties share costs, decision-making, and economics through clinical development and often commercialization — had effectively gone dormant in the back half of 2025. Capital was tight, pharma BD teams were defaulting to traditional option-based licensing, and biotech boards were reluctant to dilute their upside with 50/50 structures. That entire calculus flipped in Q1 2026. Understanding the co-dev deals deal trends 2026 requires looking at what changed on both sides of the table.

What's Driving the Trend

Pipeline crowding is forcing co-investment. In oncology, immunology, and metabolic disease — the three therapeutic areas dominating this co-dev surge — the number of competing late-stage assets has made solo bets increasingly irrational. When five companies are racing toward the same MOA in NASH or the same target in solid tumors, the cost of a Phase 3 miss is existential for mid-caps and painful even for large pharma. Co-development spreads the downside. It also, critically, gives each partner access to the other's clinical and regulatory infrastructure, which compresses timelines in a way that pure licensing cannot. Check the latest Deal Benchmarks data: median Phase 3 costs in oncology crossed $350M per pivotal trial in 2026. No rational BD team wants 100% of that exposure on a single asset when the approval probability for the class sits below 40%.

Large pharma is running out of internal shots on goal. The LOE cliff between 2026 and 2030 is well-documented — roughly $250B in branded revenue is at risk across the top 20 companies. But what's less discussed is that internal R&D productivity hasn't improved. The number of internally originated NMEs reaching Phase 3 per $1B of R&D spend has been flat since 2019. The result: BD teams are under pressure to bring in more external assets, faster. Traditional licensing gives you an option on one asset. A co-development deal gives you a seat at the table with operational control, real-time data access, and the ability to integrate the program into your commercial launch planning from Day 1. That operational depth is worth the higher upfront risk-sharing commitment.

The co-dev licensing 2026 wave also reflects a capital markets signal. Biotech companies that locked in co-development partners in Q1–Q2 2026 saw their valuations hold or appreciate, even as the broader XBI index traded sideways. Investors are rewarding structures that de-risk cash burn without fully ceding economics. A 50/50 co-dev with Novartis or Merck is now treated by public market investors as a stronger validation signal than a traditional royalty-bearing license — because it implies the partner is willing to write checks alongside you, not just collect options.

Notable Deals

Three features of this deal cluster stand out. First, every single deal in the top five involves two large-cap or upper-mid-cap companies on both sides. This is not a typical biotech-out-licenses-to-pharma dynamic. These are peer-to-peer co-development structures — AstraZeneca and Merck sharing risk, Amgen and Novartis splitting economics. That pattern is historically rare and suggests the deals are driven by genuine capability gaps rather than simple capital needs.

Second, the Janssen-AbbVie corridor is striking. Janssen appears as both licensor (with Pharmacyclics/AbbVie) and licensee (from AbbVie) within a 48-hour window. That level of cross-licensing and co-development nesting points to a broader strategic relationship emerging between J&J and AbbVie that goes beyond any single asset. BD teams watching this space should expect more multi-asset framework agreements with co-development provisions built in.

Third, Amgen's two co-dev deals — with BeiGene and Novartis — landed on the same date. Amgen has historically been a buyer, not a sharer. Its willingness to co-develop rather than acquire outright signals either increased risk aversion at the Amgen board level or, more likely, a calculation that co-development with a strong regional partner (BeiGene in China, Novartis in Europe) maximizes global value faster than going solo. Use Solidus to model how these co-dev structures compare to traditional licensing economics on a risk-adjusted basis.

What This Means for BD Teams Right Now

If you're selling, this is a structurally favorable moment — but the value capture mechanism has shifted. Pharma buyers are clearly willing to commit more operational and financial skin to deals right now. That means higher real-dollar commitments (shared costs, joint steering committees, co-investment in manufacturing). But upfront cash may compress because the buyer is taking on ongoing financial exposure. Negotiate accordingly: push for cost-sharing ratios that favor you in early development (where your risk is highest) and equalize in Phase 3. Royalty tiers matter less in a true 50/50 co-dev — focus on profit splits and opt-out penalties.

If you're buying, move fast. Twelve deals in six months means your competitors have already locked in co-development partners for the most attractive assets. The deals getting done now are concentrated in July 2026, suggesting a wave that accelerated through the summer. If you're still running traditional licensing playbooks — option exercises, milestone ladders, tiered royalties — you're bidding with an outdated currency. Assets with strong Phase 2 data in crowded indications will increasingly go to the partner offering co-development terms, not the one offering the biggest upfront check.

Deal structures gaining favor: 50/50 global co-development with territory-specific opt-outs; co-commercialization in the US with profit splits replacing royalties; joint IP ownership with cross-licensing provisions. Structures losing favor: pure option-based licenses with milestone-heavy economics; exclusive worldwide rights with royalties only. Run your next term sheet through the Ambrosia calculator to see how co-dev structures compare to traditional licensing on IRR and risk-adjusted NPV.

Benchmark your deal against current market rates. The co-dev licensing 2026 landscape is moving fast, and the economics that were standard six months ago are already stale. Use the Ambrosia calculator to stress-test your term sheets against the 12 co-development deals that have closed this year — before your counterparty does it first.